Product Launch: EliA PM-Scl

Phadia launches new fully automated PM-Scl antibody test.


Phadia is pleased to announce that the new, fully automated EliA PM-Scl test is now available.

The test is intended to be an aid in the clinical diagnosis of polymyositis/scleroderma overlap syndrome and is very useful for differential diagnosis of certain connective tissue diseases with overlapping symptoms.

PM-Scl antibodies are found in as many as 24% of patients with polymyositis/scleroderma overlap syndrome, 8% of polymyositis and 3% of scleroderma patients. PM-Scl antibodies are highly specific for this disease group. Furthermore, the new test is of great importance as a follow-up of a positive result in indirect immunofluorescence as well as a positive EliA CTD Screen.

For further information on PM-Scl click here .




As in all diagnostic testing, the diagnosis is made by the physican based on both test results and the patient history.